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Key Points 
 
-The three endothelial secretory pathways, constitutive, basal and regulated, release 
VWF in different multimeric states. 
-Apical and basolaterally released VWF follow different secretory pathways, thus 
releasing differentially multimerized protein. 
 
Abstract 
 
The Von Willebrand factor (VWF) synthesised and secreted by endothelial cells is 
central to haemostasis and thrombosis, providing a multifunctional adhesive platform 
that brings together components needed for these processes. VWF secretion can 
occur from both apical and basolateral sides of endothelial cells, and from 
constitutive, basal and regulated secretory pathways, the latter two via Weibel-
Palade bodies (WPB). Although the amount and structure of VWF is crucial to its 
function, the extent of VWF release, multimerization and polarity of the three 
secretory pathways have only been addressed separately and with conflicting 
results. We set out to clarify these relationships using polarized Human Umbilical 
Vein Endothelial Cells (HUVECs) grown on Transwell membranes. We found the 
regulated secretion of Ultra large (UL) molecular weight VWF predominantly 
occurred apically, consistent with a role in localised platelet capture in the vessel 
lumen. We found that constitutive secretion of low molecular weight (LMW) VWF is 
targeted basolaterally, toward the subendothelial matrix, using the adaptor protein 
complex 1 (AP-1), where it may provide the bulk of collagen bound subendothelial 
VWF. We also found that basally-secreted VWF is composed of UL-VWF, released 
continuously from WPBs in the absence of stimuli, and occurs predominantly 
apically, suggesting this could be the main source of circulating plasma VWF. 
Together, we provide a unified dataset reporting the amount and multimeric state of 
VWF secreted from the constitutive, basal and regulated pathways in polarized 
HUVECs, and have established a new role for AP-1 in the basolateral constitutive 
secretion of VWF.  
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Introduction 
 
 Von Willebrand factor (VWF) is a multimeric adhesive glycoprotein, 
synthesised and secreted by endothelial cells1 that is involved in many vascular 
processes and is central to haemostasis and thrombosis2. Circulating plasma and 
subendothelial VWF, both synthetized by vascular endothelial cells, have been 
ascribed different roles in haemostasis3,4. How endothelial cells control these two 
very different functional pools of VWF has not been previously explored. 
The multimeric form of secreted VWF largely dictates its haemostatic efficacy, 
since higher molecular weight VWF multimers have a much higher binding affinity for 
platelets5. Endothelial cells have two differentiated surfaces, apical, facing the vessel 
lumen, and basolateral facing the subendothelial extracellular matrix. Therefore, to 
fully understand how and where different multimeric forms of VWF make their 
contribution, we need to know not only how much is secreted apically versus 
basolaterally, but also by which one of three pathways it is delivered and the degree 
of multimerization found in each pool of this protein.  
All three secretory pathways begin at the trans-Golgi network (TGN) where 
VWF is either packaged into nascent Weibel-Palade bodies (WPBs), distinctive rod-
shaped regulated secretory organelles, or secreted directly through the ‘constitutive’ 
secretory pathway by non-descript small anterograde carriers6. WPBs store VWF for 
regulated secretion upon endothelial activation but they can also fuse and release 
VWF in the absence of activation, a process termed ‘basal’ secretion to distinguish it 
from ‘constitutive’ secretion7,8, although both collect together in the supernatant of 
unstimulated cells. Low molecular weight –VWF (LMW-VWF) is secreted by the 
constitutive pathway, in contrast to the HMW-VWF released via stimulated WPBs6,9, 
consistent with the need to control release of highly pro-thrombotic material. 
Previous studies have addressed the polarity of VWF secretion, with 
conflicting results10–14, partly because they were carried out before it was established 
that there were three pathways for secretion of VWF8. van Buul-Wortelboer and 
collegues10 used Human Umbilical Vein Endothelial Cells (HUVECs) grown on 
collagen lattices to show that unstimulated (i.e. basal plus constitutive) VWF release 
occurs at a 1:3 ratio (apical:basolateral) although the VWF quantified as basolateral 
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release also took into account all the VWF cumulatively bound to the collagen fibres 
(80%), and so is an overestimation of the true basolateral rate of unstimulated 
release. When cells were stimulated with phorbol 12-myristate 13-acetate (PMA), 
most of the VWF was released to the apical side, with no detectable change in the 
amount released basolaterally. In the same year Sporn and colleagues11 showed, 
using HUVECs grown on gelatin-coated polycarbonate membranes (3.0 µm pore 
size), that the amount of unstimulated VWF release (measured by 2h metabolic 
labelling and analysed by sodium dodecylsulfate (SDS) –polyacrylamide gel 
electrophoresis (PAGE)) into apical or basolateral chambers was approximately 
equal, and contained similar multimeric forms, including multimers of all sizes. When 
cells were stimulated with the calcium ionophore A23187, 90% of the additional VWF 
came out basolaterally, with only high multimeric VWF being released. The same 
pattern was reportedly seen with PMA stimulation. 
 A later study, again using HUVECs grown on a collagen matrix12, showed that 
PMA-stimulated release was largely apical, with no change to the levels of 
basolateral release compared to unstimulated cells. Another study measuring the 
polar release of a variety of different molecules secreted by endothelial cells, 
including VWF13, showed that HUVECs grown for 10 days on uncoated 
polycarbonate membranes (pore size 0.4 µm) secreted unstimulated VWF at a 2:1 
ratio (apical:basolateral). No stimulant was used in this study to measure regulated 
VWF release. One final study14 employed the polar Madin-Darby Canine Kidney II 
(MDCK-II) epithelial cell line stably transfected with VWF cDNA to study VWF polar 
secretion. Here again, unstimulated VWF release accumulated at a 2:1 ratio 
(apical:basolateral) compared to a ratio for PMA stimulated release of 4:1. Finally, 
live cell imaging of individual regulated exocytic events has demonstrated fusion of 
WPB to both basolateral15 and apical surfaces16. While no comparative analysis was 
done, this provides confirmation that evoked secretion can occur from both domains. 
Altogether, the direction of VWF secretion, by which pathway(s) it is released, 
and the multimeric state of the releasate at both surfaces are currently unclear. In 
particular, the relative multimeric state and the polarity of VWF secreted by the basal 
pathway have never been established. We therefore addressed all these issues 
together and in parallel.  
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Finally, the origin of plasma VWF, which is the best characterised pool of this 
molecule and is the pool assayed for diagnostic purposes, is unclear. While it is 
expected to be generated from highly multimerized material that is then cleaved by 
ADAMTS-13 down to the multimeric pattern observed in plasma, whether it arises 
from basal or regulated exocytosis is yet unclear. 
Not only is the basic description of VWF secretion confused, but the 
machinery for polarized targeting of these pathways in endothelial cells is also poorly 
understood. Since WPB are the regulated secretory VWF carriers, and AP-1 is 
essential to their formation17, this adaptor protein complex is a strong candidate to be 
in control of this pathway. Loss of AP-1 also increases unstimulated secretion but 
whether this is affecting constitutive, basal or both pathways is unclear. Furthermore, 
AP-1 is thought to mainly play a role in basolateral targeting in polarized epithelial 
cells18 and its role in polar trafficking in endothelial cells has never been explored.  
Here, we report the polarity and multimeric state of VWF secretion from 
constitutive, basal and regulated secretory pathways in polarized HUVECs, establish 
a new role for AP-1 in the constitutive secretion of VWF, and suggest a likely origin 
for plasma VWF. 
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Materials & Methods 
 
Cell Culture 
HUVECs pooled from multiple donors were obtained from Lonza (Lonza 
Walkersville, Walkersville, MD). Cells were maintained in HUVEC Growth Medium 
(HGM), composed of M199 (Gibco, Life Technologies) supplemented with 20% Fetal 
Bovine Serum, (Biosera), 30 µg/ml endothelial cell growth supplement from bovine 
neural tissue and 10 U/ml Heparin (both from Sigma-Aldrich) and used within 4 
passages.  
 
Secretion assay and vWF quantification by ELISA 
Secreted VWF was obtained by incubating confluent cells in serum-free (SF) 
medium (M199, 0.1 mg/ml BSA, 10mM HEPES-NaOH, pH 7.4) for 60 minutes. The 
medium was collected and the cells incubated further with SF medium containing 
secretagogues for 30 minutes. The remaining cells were then lysed to determine 
total VWF levels. Relative amounts of VWF were determined by sandwich ELISA as 
previously described19. 
 
Additional Materials & Methods can be found in Supplementary Information. 
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Results 
 
Multimeric states of endothelial cell VWF secreted from three different 
pathways 
Since the multimeric state of secreted VWF largely dictates its function, we 
determined the multimeric pattern of VWF secreted by the three known pathways 
from endothelial cells on plastic dishes, comparing releasate collected from confluent 
HUVECs and running the same amount of VWF in each sample (as measured by 
ELISA) on a sodium dodecylsulfate (SDS) /agarose gel. Brefeldin A8 (BFA), known 
to block direct constitutive release from the Golgi was used to distinguish between 
constitutive and basal VWF release during unstimulated conditions and two different 
widely used secretagogues, Histamine and phorbol 12-myristate 13-acetate (PMA) 
were used to stimulate regulated release. As previously reported20,21 secretagogue-
stimulated secretion, termed ‘regulated’ release, was mainly composed of Ultra-
Large (UL) and very high molecular weight multimers (HMW-VWF), while 
unstimulated release contained a broad range of multimer sizes including a higher 
proportion of low molecular weight multimers (LMW-VWF) and prominent dimer 
bands (Figure 1A and B). When BFA was used to block constitutive secretion 
leaving only basal VWF releasate, a multimeric pattern very similar to that of 
stimulated samples was observed with the exception that a strong dimer band was 
always present.  
These patterns suggest that although both are released during unstimulated 
conditions, constitutive and basally secreted VWF are differently multimerized and so 
could have very different functions. At the same time, while both believed to arise 
from WPBs, basal and regulated VWF also have different multimeric patterns, 
namely the presence of a dimer band in basal secretion, also suggesting a 
significant difference between these two pools of VWF (Figure 1C). 
 
HUVECs form a tight monolayer on Transwell membranes 
To study the polarity of VWF secretion, we first established the conditions for 
filter-grown HUVECs to form a confluent polar monolayer. HUVEC seeded at a 
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density of 105 cells per cm2 on polyester membranes (pore size 0.4 µm), formed a 
continuous monolayer within 24 h. These cells are tightly packed, and acquire tight 
junction and adherent junction markers, such as VE-Cadherin, β-Catenin and ZO-1 
(Figure 2A), that are retained for several days post seeding. HUVECs are extremely 
thin cells (3-4µm at their thickest) (Figure 2Bi), contain overlapping edges (Figure 
2Bii-iii) and form tight junctions between neighbouring cells (Figure 2Biv-v). Grown 
under these conditions, HUVEC monolayers form a barrier to diffusion (Figure 2C). 
As previously described, treatment of confluent HUVEC monolayers with Thrombin 
opened gaps between cells22 while treatment with 100µM Histamine for 30 minutes 
did not23 (Figure S1 and S3).  
 
Constitutive, Basal and Regulated VWF polar release  
 To measure unstimulated secretion, confluent HUVECs were washed, and 
incubated in Serum Free medium (SF) for 1 h, and then supernatant collected from 
the apical and basolateral chambers were assayed for the amount of VWF by ELISA. 
We found at least twice as much VWF accumulated apically compared to that 
released basolaterally, and this ratio was maintained cells grown for several days 
(Figure 3A).  
Since VWF secreted with no externally-added stimulant is a mix of constitutive 
and basal secretory pathways, BFA8 was used to distinguish between these two 
pathways. Surprisingly, BFA only reduced basolaterally secreted VWF (Figure 3B) 
revealing that most constitutive VWF secretion is directed towards the basolateral 
side of endothelial cells. Conversely, VWF released during BFA treatment and thus 
representing basal secretion, is secreted predominantly apically, with only a small 
fraction secreted basolaterally.  
 Since we were not expecting a constitutive VWF carrier to be targeted with 
any particular polarity, we determined if a synthetic secretory cargo lacking any 
targeting information would also be targeted basolaterally in this cell-system. To 
address this, HUVECs were transfected with lumGFP24, a synthetic cargo that has 
been shown to be secreted via the constitutive pathway in endothelial cells25. 
lumGFP secretion from membrane-grown cells was collected from both apical and 
basolateral chambers and a GFP ELISA showed equal amount of lumGFP released 
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apically and basolaterally (Figure 3C). Critically, this release was effectively blocked 
in both directions by BFA. Since lumGFP is secreted in a non-polarized fashion in 
polarized endothelial cells, this suggests that normal VWF constitutive secretion is 
dependent on active sorting into basolaterally-targeted carriers. 
 In order to establish the polarity of VWF secreted via the regulated pathway, 
cells on membranes were stimulated with various secretagogues. In all cases, more 
than 70% of secreted VWF accumulated apically (Figure 3D) and this same pattern 
was unchanged irrespective of how long the cells were grown on filters before assay 
(Figure 3E). As predicted, BFA did not change the pattern of regulated (i.e. 
stimulated minus unstimulated) VWF secretion (Figure 3F) 
 The degree of multimerization seen in VWF being secreted from the different 
pathways in different directions was then analysed. Equivalent amounts (units) of 
VWF in each sample (as measured by ELISA) were loaded and analysed by agarose 
gel electrophoresis. Although our ELISA results predicted that unstimulated apical 
VWF should be mostly basal secretion, composed of mostly UL-VWF multimers 
together with a dimer band, we still do see a high proportion of LMW-VWF in this 
sample, which disappears with BFA (Figure 3G, lane 1 and 3). This would suggest 
that unstimulated apical VWF releasate is composed of mostly of UL multimeric 
basal VWF but also contains a small amount of constitutive VWF (i.e. BFA sensitive), 
which, with its LMW-VWF multimers, is probably underestimated in an ELISA and 
may be overrepresented on a gel.  
Our ELISA results also suggest that unstimulated basolateral VWF secretion 
is mainly composed of constitutive VWF, with a smaller proportion of basal secretion 
(Figure 3B). This is matched by the multimer gels, where LMW-VWF multimers, 
which disappear with BFA, are seen along with the basally secreted UL-VWF bands 
(Figure 3G, lane 2 and 4).  
We also noticed that when BFA was used, leaving only basal VWF, a strong 
dimer band remained in the apical unstimulated releasate but surprisingly 
disappeared from the basolateral sample (Figure 3G, lane 3 and 4). Further, in the 
Histamine stimulated samples, along with the expected UL-VWF multimers, a dimer 
band unpredictably appeared in the apically secreted material (Figure 3G, lane 5 
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and 7). We currently have no explanation for this minor but surprising and 
consistently present phenomena. 
 
AP-1 and VWF polar targeting 
 Most studies investigating the role of AP-1 in polarized targeting have done so 
by knocking-out or downregulating the amount of the AP-1µ1 subunit, one of the 
core subunits of AP-1. Most of this work has investigated the role of the epithelial-
specific26 AP-1µ1B subunit, and while HUVECs do not express this transcript 
(Figure 4A), they do express the  more ubiquitous AP-1µ1A variant, also implicated 
in polarized trafficking in some studies18. Here we used specific siRNA to effectively 
down regulate AP-1µ1A in HUVECs (herein referred to as siAP-1M1) using two 
rounds of nucleofection (Figure 4B). Similar to previous results from our lab using a 
VWF-expressing HEK293 cell model17, downregulation of AP-1µ1A in HUVECs 
impairs WPB formation (Figure S2) with a resulting increase in unstimulated VWF 
secretion (Figure 4C, non-striped bars) plus a decrease in stimulated VWF release 
(Figure 4D), when cells were grown on plastic wells. Critically, this was not due to 
Golgi fragmentation in siAP-1M1 treated cells27,28 (Figure S2) since we know this 
would affect WPB biogenesis29. Using BFA, we can also now show that most of this 
increase in unstimulated VWF release in siAP-1M1 treated cells is due to an 
increase in secretion via the constitutive pathway, since a larger proportion was 
blocked with BFA (Figure 4C). These results confirm that AP-1 is necessary for the 
sorting of VWF into WPB, and suggest that if this is disrupted, then the displaced 
VWF is continuously secreted through the constitutive pathway. 
In order to determine if AP-1 is also involved in the polarized targeting of VWF 
from the different secretory pathways, during the second round of siRNA 
nucleofection HUVECs were seeded onto filters, and allowed to grow for two days. 
Importantly, siAP-1M1 treatment did not alter monolayer permeability even after 
Histamine stimulation (Figure S3). Secreted VWF was collected and assayed by 
ELISA revealing an increase in the total amount of unstimulated VWF secreted as is 
seen on plastic-grown cells (Figure 5A, total bars). As with cells grown on plastic 
(Figure 4C), this increase reflected a rise in the amount of VWF secreted via the 
constitutive pathway (Figure 5B, larger proportion blocked by BFA treatment). 
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Critically, as opposed to control cells where constitutive secretion of VWF is mostly 
basolateral, in siAP-1M1 treated cells it is secreted in both directions, losing its 
exclusive basolateral targeting. Ablation of another AP-1 subunit (γ-adaptin) 
confirmed these results (Figure S4), strongly suggesting that AP-1 is involved in the 
basolateral targeting of constitutive VWF carriers in endothelial cells.  
To confirm if this effect on constitutive secretion was specific to VWF, we 
again used the lumGFP construct to check if AP-1 had any effect on the polarity of 
its secretion. The amount, sensitivity to BFA and polarity of lumGFP secretion 
(Figure 5C) were not affected in siAP-1M1 treated cells, confirming a specific effect 
of AP-1 on the polarity of VWF constitutive carriers and not a general function of this 
adaptor on all constitutive carriers in endothelial cells. The polarity of basal (Figure 
5B, hatched bars) and regulated VWF release (Figure 5D) was not affected in siAP-
1M1 treated cells, with the majority of VWF still being released apically. 
 Multimer gels of VWF secreted from siAP-1M1 treated cells were analysed 
and, as predicted from the secretion assay results (Figure 5A, B, D), we observed 
little change in the multimeric state of VWF secreted from siAP-1M1 treated cells 
compared to control cells. The multimeric pattern from Histamine-stimulated cells 
was identical and that from unstimulated cells was very similar when compared to 
control cells (Figure 5E) except for an increase in the proportion of LMW-VWF 
bands in the siAP-1M1 samples, due to the increase in the proportion of 
constitutively secreted VWF (Figure 5E, most clearly seen by the increase in 
tetramers and hexamers in lane 3-4 vs 1-2). This was not unexpected since, in 
addition to the increased constitutive release, basal and even regulated exocytosis 
are both still occurring, albeit at reduced levels. 
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Discussion 
 
In this study, we establish for the first time, the relative amounts and 
multimeric states of VWF released through all three known secretory pathways; 
constitutive, basal and regulated release. We show that constitutively secreted VWF 
is composed of mainly LMW-VWF multimers; that basally secreted VWF, originating 
from the continuous release of VWF from WPB in the absence of added stimuli, is 
composed of mostly UL-VWF multimers together with a prominent dimer band; and 
that regulated VWF release is exclusively composed of UL-VWF multimers (Figure 
1). Since the discovery of the basal pathway for VWF secretion from endothelial 
cells8, the multimeric state of this continuous source of VWF had not been previously 
established and thus its functional role has never been addressed. Our current 
findings suggest that the multimeric state of VWF secreted from the three pathways 
is different and so could have different physiological functions. 
We go further and establish the amount and multimeric states of VWF from all 
three pathways in a polar endothelial context. The need to revisit the polarity of VWF 
secretion, mainly investigated 25 years ago, reflects firstly the fact that this analysis 
dates from before the clarification by Giblin et al8 of the three possible secretory 
pathways taken by VWF (constitutive, basal and regulated). Secondly, the literature 
from that time is somewhat confusing, with different results being presented. Finally, 
the relationship between all three pathways and the multimeric state of VWF has not 
been previously addressed, let alone in a polarized cell system. We have attempted 
to put all these aspects together into an overall comprehensive picture of polarized 
VWF secretion and multimerization using primary human endothelial cells.  
We find that the largest amount of stimulated (regulated) VWF secretion 
occurs apically, with varying total amounts depending on the secretagogues used 
(Figure 6). This is in line with the majority of previous in vitro10,12,14 and in vivo 
studies30. This form of secreted VWF is also composed of mainly UL-VWF 
multimers. This is in line with the currently accepted, yet experimentally unsupported 
dogma, that most highly multimerized VWF is secreted mainly towards the apical 
(lumen) surface of endothelial cells, which we now prove experimentally for the first 
time. The lumen of the blood vessel is where circulating platelets can be recruited by 
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locally released UL-VWF upon stimulation, and where endothelial-anchored VWF 
strings can initiate a haemostatic plug, in a tightly localized and controlled fashion31. 
Thus, regulated VWF release can be thought of as the critical pool for emergency 
use only, where apically released VWF strings along with basolaterally released 
anchoring VWF is restricted to the site of injury, while being of the highest platelet-
binding activity. 
We also find that twice as much unstimulated VWF accumulated apically 
compared to that released basolaterally, in line with reports from Narahara et al13 
and Hop et al14. We go further and use BFA to distinguish between VWF released 
constitutively versus basally, observing for the first time that basal VWF secretion 
occurs predominately to the apical side of endothelial cells, with only a small fraction 
being secreted basolaterally (Figure 6). These findings suggest that this form of 
VWF, continuously secreted along the vascular tree could be the major source of 
plasma VWF. Once secreted from endothelial cells through the basal pathway, this 
UL-VWF form is cleaved by the endothelial secreted32 metalloprotease ADAMTS-
1331, generating the more intermediate VWF multimers found in plasma (Figure 1), 
allowing control of levels of highly pro-thrombotic VWF in circulation. 
Most in vitro work on exocytosis has focussed on regulated release, and the 
short collection times (15-60min) used in analyses emphasise the relative amount of 
secretagogue-driven release, giving the impression of this being the main source of 
VWF in plasma. However, we suggest that this may be mistaken: if basal release is 
only 5-20% of secretagogue-driven secretion (depending on the secretagogue used) 
per unit time, then for regulated and basal secretion to both generate an equal 
amount of circulating VWF, 5-20% of the WPB-containing endothelium would need 
to be activated at any given time- this seems extremely unlikely. 
Our data are also consistent with the need for targeting of VWF into WPB for 
appropriate multimerization to occur during biosynthesis: both regulated and basal 
pathways release highly multimerized VWF, in contrast to the constitutive pathway. 
Why we see a significant dimer band in basally secreted VWF is as yet unclear, 
although the internal milieu of these two carriers (basal WPBs vs regulated WPBs) 
are likely to be different, perhaps having different retentions times inside the cell that 
could potentially drive differential multimerization patterns. Whether the dimers only 
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reflect the differential maturation of the two populations of WPB, or actively 
contribute to some difference in function is as yet unknown.  
Previous findings from our lab (see Supplementary Figure S4C in 29) and 
others31,33,34 have shown that unstimulated cells only rarely form VWF strings under 
flow. This is consistent with our proposed role for basal VWF, again suggesting that, 
although being of similar high multimeric states (except for the dimer band), basal 
and regulated VWF play different functional roles. Whether basally-secreted VWF is 
incapable of producing strings or this difference simply reflects the exocytic mode of 
this secretory pathway: low numbers of randomly-distributed exocytic events will 
preclude co-operative action in bringing together the material from more than one 
exocytic event that could well be needed to drive string formation. 
Finally, the requirement to sustain a steady source of plasma VWF to 
maintain adequate haemostasis is crucial, as observed in Type 1 and Type 3 von 
Willebrand disease patients35. Basally released VWF provides such a source since it 
is (1) continuously secreted, (2) of a high multimeric state such that it could act as 
the precursor of plasma VWF, (3) does not produce VWF strings to initiate thrombus 
formation, and (4) is secreted mostly apically towards the vessel lumen, four critical 
requirements for an adequate and reliable source of circulating plasma VWF.  
Finally, our results also show that constitutive VWF release is, surprisingly, 
exclusively basolaterally targeted and We also report a novel role for AP-1 in this 
delivery along with its known role in WPB biogenesis17. This is in agreement with its 
long established role in basolateral targeting in epithelial cells. How AP-1 acts in 
sorting VWF at the TGN is puzzling. The AP-complexes involved in sorting during 
the formation of clathrin coated vesicles are generally recruited to membranes by 
binding to the cytoplasmic tails of integral transmembrane proteins36. How then does 
VWF, a protein with no transmembrane domains, recruit AP-1? To date, there is no 
identified abundant integral membrane VWF-binding protein to recruit AP-1. We note 
that heterologous expression of VWF results in formation of WPB in some cells but 
not others37, thus some cell-specific machinery must be in operation, but this elusive 
component has not yet been identified. 
Finally: why is constitutively released VWF actively targeted for basolateral 
release? Substrate-bound VWF is known to promote anchoring along with collagen, 
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at least in vitro, of circulating plasma VWF38,39 and platelets40 under shear flow, 
which is critical in producing a haemostatic plug during vascular injury when the 
entire endothelial layer has been lost and the subendothelial matrix is exposed to 
shear stress. We note that endothelial cells specifically target this material for 
incorporation into the matrix via AP-1, implying that this is not non-specific leakage 
but a deliberate provision of this pool, and that the VWF provided in this way is of low 
multimeric state. Since the vast majority of in vitro studies investigating the role of 
immobilised VWF use human plasma as their source of VWF (which contains both 
LMW and HMW, but is devoid of UL multimers) it could be that constitutively 
secreted VWF from endothelial cells is itself the source of functional sub-endothelial 
VWF, and/or it acts to increase the efficiency of recruitment of plasma VWF. Further 
in vitro studies comparing the functional differences when either UL-VWF or LMW-
VWF are used as source material for matrix-bound VWF would help to dissect this 
issue.  
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Figure Legends 
 
Figure 1. Multimeric states of endothelial cell VWF secreted from three 
different pathways. 
(A) Representative multimer pattern of secreted VWF collected for 30 minutes 
from unstimulated, treated with 5µM of Brefeldin A (‘+BFA’) for 1 h prior and 
during secretion collection, treated with 100µM Histamine or 100 ng/mL of 
PMA. VWF ELISA was used to measure the amount of VWF secreted in all 
conditions and the same units of VWF were loaded on an SDS/ agarose gel 
(migrations shown from top to bottom). A parallel sample of human plasma is 
shown for comparison (‘Plasma VWF’). Relative VWF amount ratios in this 
experiment: 1:1:5:16; Constitutive: Basal: Histamine: PMA. 
(B) Representative line plots from the multimer patterns shown in (A). A.U; 
Arbitrary Units. 
(C) Diagram of multimer patterns of plasma VWF and VWF secreted via the 
Constitutive, Basal and Regulated secretory pathways from endothelial cells. 
UL, Ultra Large; HMW, High Molecular Weight; LMW, Low Molecular Weight. 
 
Figure 2. Confluent HUVECs on polyester membranes form a polar monolayer. 
(D) Immunofluorescence of confluent HUVECs grown on polyester membranes 
for the times indicated (days) and stained for the cell’s nucleus (DAPI)(blue), 
VWF (red) and either VE-Cadherin, β-catenin or ZO-1 (green). Scale bar 
50µm. 
(E) TEM of a cross-section of a HUVEC (i) with the TGN to the right of the 
nucleus (*). Two examples of TEM cross-sections of overlapping tips between 
neighbouring HUVECs (ii-iii) and the close contact formed between the cell 
membranes of two adjacent cells (iv-v) with ‘fuzz’ like structure typical of Tight 
Junctions in epithelial cells (arrows). Scale bar: i 2µm, ii-iii 1µm, iv-v 300nm. 
(F) Dextran permeability assay, where 1 mg/ml of 40kD-FITC-Dextran was 
loaded on the apical chamber of empty membranes (‘No cells’), 2 day 
confluent unstimulated HUVECs (‘-‘), or treated with 100µM Histamine 
Lopes da Silva and Cutler 
21 
 
(‘+Hist’) or 2.5 U/ml Thrombin (’+Thro’) to open extracellular pores. The 
amount of FITC-Dextran in the basolateral chamber was measured after 
incubation with FITC-Dextran in the apical chamber for 30 minutes. Mean of 
triplicate wells (with SD), as % of ‘No cells’ control sample. (*p<0.05, 
**p<0.005, n.s. not significant). 
 
 
Figure 3. Polarity of VWF secretion. 
(A) Unstimulated VWF secretion on Transwell membranes of HUVECs grown for 
the time indicated (in days), expressed as a % of secreted VWF from the total 
VWF in each sample (secreted plus lysate). Results standardized to ‘D1’ 
sample. Representative experiment, mean of three replicates with SD. 
(B) Unstimulated VWF secretion from HUVECs grown on Transwell membranes 
of HUVECs grown for 2 days. Cells were either left untreated (‘-BFA’) or were 
treated with 5µM of Brefeldin A (‘+BFA’) for 1 h prior and during secretion 
collection from both chambers. Results standardized to control ‘-BFA’ sample. 
Mean of three independent experiments with SEM. (**p<0.005). 
(C) Lum-GFP secretion on Transwell membranes. HUVECs were nucleofected 
with lum-GFP construct and seeded on Transwell membranes for 30 h prior to 
secretion assay. Cells were treated with either Control (‘-BFA’) or 5µM of 
Brefeldin A (‘+BFA’) for 1 h prior and during secretion collection from both 
chambers. Amount of lumGFP secreted expressed as a percent of total GFP 
in each sample (secreted plus lysate). Representative experiment, mean of 
three replicates with SD. (***p<0.0005). 
(D) Stimulated VWF secretion on Transwell membranes of HUVECs grown for 2 
days. Cells were stimulated with either 100µM Histamine (‘Hist’), 100µM 
Histamine plus 100µM Adrenaline plus 100mM IBMX (‘Hist +Adr +IBMX’), 
40ng/mL VEGF, or 100 ng/mL PMA for 30 minutes while secreted VWF was 
collected from both chambers. Amount of VWF secreted expressed as a 
percent of total VWF in each sample (secreted plus lysate). Representative 
experiment, mean of three replicates with SD. 
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(E) Histamine VWF secretion on Transwell membranes of HUVECs grown for the 
time indicated (in days), expressed as a percent of total VWF in each sample 
(secreted plus lysate), relative to control (‘D1’) sample. Results standardized 
to ‘D1’ sample. Representative experiment, mean of three replicates with SD. 
(F) Histamine VWF secretion on Transwell membranes of HUVECs grown for 2 
days. Cells were treated with either Control (‘-BFA’) or 5µM of Brefeldin A 
(‘+BFA’) for 1 h prior and during 30 min 100µM Histamine stimulation and 
secretion collection from both chambers. Results standardized to control ‘-
BFA’ samples. Mean of three independent experiments with SEM.  
(G) Representative multimer pattern of secreted VWF collected from unstimulated 
and Histamine stimulated HUVECs. Cells were treated with either Control (‘-
BFA’) or 5µM of Brefeldin A (‘+BFA’) for 1 h prior to and during VWF secretion 
collection in both chambers. Unstimulated secretion was collected for 1 h 
while 100µM Histamine stimulated secretion was collected for 30 min. The 
same units of VWF (as measured by ELISA) was loaded for all samples. VWF 
ELISA quantification corresponding to these samples are shown in Figure 3B 
and F. A, apical chamber; B, basolateral chamber. Lanes 1-4, unstimulated 
releasate, lane 5-8 Histamine stimulated releasate. 
 
Figure 4. AP-1 regulates VWF sorting into WPBs in HUVECs.  
(A) PCR bands to detect the presence of AP-1 subunits in HUVECs and HT-29 
cells. Primers specific for Actin (‘Act’), AP-1µ1A (‘µ1A’), AP-1µ1B (‘µ1B’) and 
AP-1γ1 (‘γ1’) were used for amplification of cDNA made from extracted RNA 
from cell lysates. 
(B) qRT-PCR measuring the efficiency of mRNA down-regulation of the AP-1µ1A 
subunit in HUVECs after 2 rounds of nucleofection with siRNA specifically 
targeting AP-1µ1A (siAP-1M1), 2 days apart. Mean of 12 experiments with 
SEM (***p<0.0005). 
(C) Unstimulated VWF secretion on plastic of HUVECs either Mock nucleofected 
or nucleofected with siAP-1M1. Cells were treated with either Control (‘-BFA’) 
or 5µM of Brefeldin A (‘+BFA’) for 1 h prior and during VWF secretion 
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collection. Results standardized to ‘Mock –BFA’ samples. Mean of 5 
independent experiments with SEM. (***p<0.0005). 
(D) Histamine (100µM) stimulated VWF secretion on plastic of HUVECs either 
Mock nucleofected or nucleofected with siAP-1M1. Results standardized to 
Mock samples. Mean of 5 independent experiments with SEM. (***p<0.0005). 
 
Figure 5. AP-1 regulates basolateral sorting of VWF constitutive carriers.  
(A) Unstimulated VWF secretion on Transwell membranes of HUVECs either 
Mock nucleofected or nucleofected with siRNA specifically targeting AP-1µ1A 
(siAP-1M1). Results standardized to Mock samples. Mean of 5 independent 
experiments with SEM. (*p<0.05, **p<0.005). 
(B) Unstimulated VWF secretion on Transwell membranes of HUVECs either 
Mock nucleofected or nucleofected with siAP-1M1. Cells were treated with 
either Control (‘-BFA’) or 5µM of Brefeldin A (‘+BFA’) for 1 h prior and during 
VWF secretion collection. Results standardized to Mock samples. Mean of 3 
independent experiments with SEM. (**p<0.005). 
(C) Lum-GFP secretion on Transwell membranes. HUVECs were either Mock 
nucleofected or nucleofected with siRNA specifically targeting AP-1µ1A 
(siAP1) and lumGFP construct was added during the second round of 
nucleofection and seeded on Transwell membranes for 30 h prior to secretion 
collection. Cells were treated with either Control (‘-BFA’) or 5µM of Brefeldin A 
(‘+BFA’) for 1 h prior and during secretion collection in both chambers. 
Amount of lumGFP secreted expressed as a percent of total GFP in each 
sample (secreted plus lysate). Mean of 3 replicates with SD. (***p<0.0005). 
(D) Histamine (100µM) stimulated VWF secretion on Transwell membranes of 
HUVECs either Mock nucleofected or nucleofected with siRNA specifically 
targeting AP-1µ1A (siAP1). Results standardized to Mock samples. Mean of 7 
independent experiments with SEM.  
(E) Representative multimer pattern of secreted VWF collected from unstimulated 
and 100µM Histamine stimulated HUVECs either Mock nucleofected or 
nucleofected with siAP-1M1. Unstimulated secretion was collected for 1 h 
while Histamine stimulated secretion was collected for 30 min. The same units 
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of VWF (as measured by ELISA) was loaded for all samples. VWF ELISA 
quantification corresponding to these samples are shown in Figure 5A and D. 
A, apical chamber; B, basolateral chamber. Lanes 1-4, unstimulated 
releasate, lane 5-8 Histamine stimulated releasate. 
 
Figure 6. The pathways of VWF secretion and their polarity. 
Diagram of a blood vessel showing the relative amount (length of arrows) and 
direction of secreted VWF from the three different secretory pathways from 
endothelial cells. The direction of VWF secreted either to the apical (vessel lumen) or 
the basolateral side (subendothelial matrix) of endothelial cells from each pathways 
is indicated by the direction of the arrows.  
Release from the constitutive pathway, which is Brefeldin A -sensitive, is exclusively 
to the basolateral side of endothelial cells, and is mostly composed of LMW-VWF 
multimers. Basal VWF release, the continuous release from WPBs, occurs mostly 
towards the apical side of endothelial cells with a small amount secreted 
basolaterally, and is composed of UL-VWF multimer together with a dimer band. 
Regulated release, originating from WPB after a secretagogue stimulant, occurs 
predominantly to the apical side with some release to the basolateral side and is 
composed of exclusively UL-VWF multimers. 
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